The post Aposense Receives Grant for Expanding its Molecular-Nano-Motors (MNMs) Delivery Platform to mRNA appeared first on Aposense.

Petach Tikva, and Ness-Ziona, Israel. (April 26, 2020)

SirVir Ltd., headed by Professor Roger Kornberg, Nobel Prize Laureate in chemistry, and funded by Sir Leonard Blavatnik through an affiliate Access Industries, Inc., is a subsidiary of Aposense Ltd. and is active in the field of genetic therapies for respiratory viral infections. Aposense is an innovative Israeli biopharmaceutical company which develops first-in-class Molecular Nano-Motors (MNMs) utilizing membrane electrical potential for trans-membrane delivery of genetic drugs, including siRNA.

SirVir recently entered into a collaborative Research and Development Project with the Israeli Institute for Biological Research (IIBR) with the goal of accelerating development of a genetic therapy for the pandemic of Corona virus COVID-19 based on Aposense’s proprietary gene delivery platform that was licensed to SirVir. Sirvir and IIBR are now pleased to announce success in the first pre-clinical study, performed in cell culture, which evaluated anti-viral activity of an Aposense MNM construct comprising siRNA in eradication of COVID-19 to the extent of 90%.

The Israel Institute for Biological Research (IIBR) is a governmental, cutting-edge applicable research institute, specializing in the fields of biology, chemistry and environmental sciences. IIBR recruits leading Israeli scientists and support staff and benefits from facilities built to serve the topmost research and strict safety standards. About Coronavirus On January 7, 2020, a novel coronavirus (COVID-19) was identified as the cause of pneumonia cases in Wuhan City, Hubei Province of China, and thereafter spread worldwide to be a pandemic, with very large morbidity and mortality. Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses are transmitted between animals and people and can evolve into strains not previously identified in humans.

The post SirVir obtains positive results in pre-clinical experiment against COVID-19 appeared first on Aposense.

PETACH TIKVA – June1, 2020 – Aposense, LTD. announced today that it has signed an agreement with Processa Pharmaceuticals, Inc. (OTCQB: PCSA) to license out the patent rights and the know-how to develop and commercialize their next generation irinotecan cancer drug, ATT-11T.

Irinotecan metabolizes to SN-38, an active anti-cancer moiety, used as first and second line therapy for many types of cancer (e.g., metastatic colorectal, small cell lung, pancreatic). Although irinotecan has a narrow therapeutic window and dose limiting adverse effects including an FDA “Black Box” warning for both neutropenia and severe diarrhea, irinotecan achieved peak annual sales of US$1.1 billion. ATT-11T is a novel lipophilic anti-cancer pro-drug, being developed for the treatment of the same solid tumors as prescribed for irinotecan. This pro-drug is a conjugate of a specific proprietary Aposense molecule connected to SN-38, the active metabolite of irinotecan. The proprietary Aposense molecule of ATT-11T allows ATT-11T to bind to cell membranes, to form an inactive pro-drug depot on the cell with SN-38, preferentially accumulating in the membrane of tumors cells and the tumor core. This unique characteristic generates a therapeutic window that is wider than that of Irinotecan, thus providing an anti-tumor effect of ATT-11T occurring at a much lower dose than irinotecan, concurrent with a milder adverse effect profile than irinotecan.

This wider therapeutic window will likely lead to a better anti-cancer therapeutic response, with less
side effects of ATT-11T compared to irinotecan. “This licensing of the ATT-11T to Processa is aligned with Aposense’s strategy as a platform technology company which commercializes its IP assets”. Said Yuval Gottenstein Aposense’s Chief Executive Officer.

The licensing agreement is conditioned upon Processa’s closing of the Satisfactory Financing Round and up-listing to the NASDAQ or NYSE. Subject to the terms of the Agreement and upon satisfaction of the conditions, Aposense will grant Processa a worldwide (excluding China), royalty-bearing right and license, including the right to sublicense. Under the terms of the Agreement, Aposense would receive shares in Processa with an aggregate value of $2.5M and could receive up to a maximum of $125M in potential development and sales milestones, as well as royalties of 7% based on net sales.

About Aposense, LTD.
Aposense is a highly innovative Israeli bio-pharmaceutical company, specializing in development of novel drugs, utilizing membrane electrical forces. Among others, Aposense developed a universal platform entitled Molecular Nano-Motors (MNMs) for the delivery of genetic drugs, such as siRNA, into cells.
https://aposense.com/

About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions, medical conditions where patients need treatment options that will improve survival and/or quality of life. The Company has assembled a proven regulatory science development team, management team, and Board of Directors. The Processa development team has been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. For more information, please visit http://www.processapharma.com.

The post Aposense enters into an out-licensing agreement with Processa Pharmaceuticals appeared first on Aposense.